Emma Reeve - PAREXEL International Interim CFO, Corporate Vice President Controller

PRXL -- USA Stock  

null 88.06  0.04  0.0454%

  President
Ms. Emma Reeve serves as Vice President, Corporationrationrate Controller of the Company. She is no longer Interim Chief Financial Officer of the Company, effective June 1, 2017. Since September 2014 she has also served as Corporationrationrate Controller of the Company and is responsible for SEC Reporting, Investor Relations, Financial Planning and Analysis, Shared Service Centers and Process Improvement. From May 2012 to August 2014, she served as Head of Finance and Administration for Novartis Pharma Schweiz, a pharmaceutical company. From January 2008 to April 2012, she served as Vice President, Global Head Business Planning and Analysis for Novartis Vaccines and Diagnostics, a division of Novartis. Prior to this, she held several leadership financial positions, including serving as CFO for two biopharmaceutical companies, and finance leadership positions with BristolMyers Squibb and Merck. Ms. Reeve has a degree in Computing Science from the Imperial College of Science and Technology, University of London and is a Chartered Accountant.
Age: 54  President Since 2017      
781 487-9900  http://www.parexel.com
Reeve has more than 20 years of experience in life sciences financial management. Prior to joining PAREXEL, Ms. Reeve served in various senior financial positions in the pharmaceutical industry, including Head of Finance and Administration for Novartis Pharma Switzerland and Global Head Business Planning & Analysis for Novartis Vaccines and Diagnostics. Prior to joining Novartis in 2008, she held several leadership financial positions, including serving as CFO for two biopharmaceutical companies.

Management Efficiency

The company has return on total asset (ROA) of 6.72 % which means that it generated profit of $6.72 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 16.93 % meaning that it created $16.93 on every $100 dollars invested by stockholders.
The company currently holds 671.5M in liabilities with Debt to Equity (D/E) ratio of 105.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PAREXEL International has Current Ratio of 1.42 which is within standard range for the sector.

Similar Executives

Showing few of many executives

PRESIDENT Since

Michael PartridgeVertex Pharmaceuticals Incorpor
N/A
Michael StewartPerrigo Company plc
2004
Andrew FentonZoetis
2018
Stefan WeiskopfZoetis
2013
John HendricksonPerrigo Company plc
2016
Paul WeningerPerrigo Company plc
2015
Amit BiswasDr Reddys Laboratories Ltd
2016
Alok SonigDr Reddys Laboratories Ltd
2015
Paul SilvaVertex Pharmaceuticals Incorpor
2019
Marc CouckePerrigo Company plc
N/A
Joyce LeeZoetis
2012
Raghav ChariDr Reddys Laboratories Ltd
2013
Peter PowchikRegeneron Pharmaceuticals
2006
Jatin ShahPerrigo Company plc
2005
Roxanne LaganoZoetis
2015
Marion McCourtRegeneron Pharmaceuticals
2018
Thomas FarringtonPerrigo Company plc
2015
M RamanaDr Reddys Laboratories Ltd
2018
K RaoDr Reddys Laboratories Ltd
2016
Christopher FenimoreRegeneron Pharmaceuticals
2017
Douglas McCorkleRegeneron Pharmaceuticals
2007

Entity Summary

PAREXEL International Corporationration, a biopharmaceutical services company, offer clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology solutions and services for pharmaceutical, biotechnology, and medical device industries worldwide. PAREXEL International Corp (PRXL) is traded on NASDAQ in USA and employs 18,600 people.

PAREXEL International Leadership Team

Michelle Graham, Chief Human Resource Officer, Senior Vice President
Ulf Schneider, Chief Administrative Officer, Senior Vice President
Thomas Senderovitz, Senior Vice President - Clinical Research Services
Dana Callow, Presiding Independent Director
Emma Reeve, Interim CFO, Corporate Vice President Controller
Josef Rickenbach, Founder, Chairman and CEO
Patrick Fortune, Independent Director
Eduard Holdener, Independent Director
Simon Harford, CFO, Senior Vice President
Joshua Schultz, Senior Vice President-Worldwide Head of PAREXEL Access
Gadi Saarony, Senior Vice President - Clinical Research Services
Ellen Zane, Director, Member of Compensation Committee, Member of HR Committee, CEO of Tufts Medical Center and President of Tufts Medical Center
Christian Dreger, Senior Vice President - Parexel Access and Parexel Consulting
Xavier Flinois, President - Perceptive Informatics
Douglas Batt, Sr. VP, General Counsel and Secretary
Sybrand Pretorius, Senior Vice President Chief Scientific Officer
Maykin Ho, Director
Richard Love, Independent Director
Ronald Aldridge, Sr. Director, Investor Relations
Mark Goldberg, President COO
Roland Andersson, Senior Vice President - Clinical Research Services
Christopher Lindop, Independent Director
Ingo Bank, CFO and Sr. VP
David Godwin, Senior Vice President-Global Business

Stock Performance Indicators

Current Sentiment - PRXL

PAREXEL International Investor Sentiment

Most of Macroaxis users are at this time bullish on PAREXEL International Corp. What is your perspective on investing in PAREXEL International Corp? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Currently Active Assets on Macroaxis

TWTR   
Purchased over 50 shares of
few hours ago
Traded for 1.0
MGTI   
Purchased over 50 shares of
few hours ago
Traded for 1.0
PVCT   
Purchased over 10K shares of
few hours ago
Traded for 1.0
BTSC   
Purchased over 10K shares of
few hours ago
Traded for 1.0
ALNY   
Purchased few shares of
few hours ago
Traded for 1.0
Additionally take a look at Your Equity Center. Please also try Equity Analysis module to research over 250,000 global equities including funds, stocks and etfs to find investment opportunities.
Search macroaxis.com